Compare · ABBV vs AVDL
ABBV vs AVDL
Side-by-side comparison of AbbVie Inc. (ABBV) and Avadel Pharmaceuticals plc (AVDL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and AVDL operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $464.58B, about 1017.8x AVDL ($456.5M).
- Over the past year, ABBV is up 26.3% and AVDL is up 45.8% - AVDL leads by 19.5 points.
- ABBV has hit the wire 17 times in the past 4 weeks while AVDL has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 15 for AVDL).
- Company
- AbbVie Inc.
- Avadel Pharmaceuticals plc
- Price
- $262.89-1.07%
- $21.67+0.16%
- Market cap
- $464.58B
- $456.5M
- 1M return
- -0.10%
- +0.77%
- 1Y return
- +26.35%
- +45.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 15
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Latest ABBV
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest AVDL
- SEC Form 15-12G filed by Avadel Pharmaceuticals plc
- Former 10% Owner Weiss Asset Management Lp sold $233,353,092 worth of Ordinary Shares (11,112,052 units at $21.00) (SEC Form 4)
- New insider Weiss Asset Management Lp claimed ownership of 11,112,052 units of Ordinary Shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form 4 filed by Chief Operating Officer Rodriguez Susan
- Director Thornton Peter J. returned $2,416,260 worth of Ordinary Shares to the company (115,060 units at $21.00), closing all direct ownership in the company (SEC Form 4)